Alex Gloor Partner


Speaks:  English

Year of Call: 2012 - Ontario

Primary phone: +1 613-786-0172

Fax: +1 613-563-9869

Email: alex.gloor@gowlingwlg.com

Download vCard


Primary office:  Ottawa




Alex Gloor

Alex Gloor is a partner in the Intellectual Property Group in Gowling WLG's Ottawa office.

Alex's practice focuses on intellectual property litigation matters, with a primary focus on patent litigation. Alex has represented clients in proceedings brought under the Patented Medicines (Notice of Compliance) Regulations, patent impeachment and infringement actions, judicial reviews, and in matters under the Trademarks Act and the Industrial Design Act.

He regularly appears as counsel and has successfully presented arguments before the Federal Court, Federal Court of Appeal, Ontario Superior Court, and Ontario Court of Appeal.

Alex is a member of the firm's Life Sciences group and regularly acts for innovative pharmaceutical manufacturers. In addition to litigation matters, Alex advises pharmaceutical clients on regulatory issues such as patent listing, data protection and certificates of supplementary protection. Alex also has experience representing clients in the manufacturing, agriculture, consumer goods and material sciences industries.

Alex is a part-time professor at the University of Ottawa where he has taught the Intellectual Property Law class to upper-year law students for six years. Alex has also authored several articles discussing patent litigation in Canada.

Alex has volunteered with the community and legal aid services program and with Pro Bono Students Canada.

Alex has a background in chemistry and has experience working as a researcher in a chemical engineering laboratory. Alex graduated with a JD from Osgoode Hall Law School, where he won numerous awards for his academic achievements.

Career & Recognition

Filter timeline:
  • 2019

  • 2012

    • Qualifications (Year of Call/Admission, etc.)
       2012
      Year of Call, Ontario
  • 2011

    • Education
       2011
      Osgoode Hall Law School, JD
  • 2008

    • Education
       2008
      University of Western Ontario, B.Sc. (Hons. with distinction)

Representative Work

Alex has appeared as counsel of record in numerous cases before the Federal Court, Federal Court of Appeal, and Ontario Superior Court. A sample of cases includes:

  • T-971-22: Lundbeck Canada Inc. et al v Sandoz Canada Inc. (TRINTELLIX®)
  • T-192-22: Novartis Pharmaceuticals Canada Inc et al v Teva Canada Limited (ENTRESTO®)
  • T-668-21 and T-1213-21: Lundbeck Canada Inc et al v Apotex Inc. (TRINTELLIX®)
  • T-886-20: Galderma Canada Inc. et al v Sandoz Canada Inc. (APPRILON®)
  • T-578-20: Galderma Canada Inc. v Taro Pharmaceuticals Inc. et al (TACTUPUMP® FORTE)
  • T-438-19: Double Diamond Distribution, Ltd. V Crocs Canada Inc et al
  • T-1960-18 and T-2093-18: Bayer Inc. et al v Teva Canada Limited (T-1960-18) and Bayer Inc. et al v Apotex Inc. (T-2093-18) (XARELTO®)
  • T-1163-18 and T-220-19 (A-146-20): Biogen Canada Inc. v Taro Pharmaceuticals Inc (T-1163-18) and Biogen Canada Inc v Pharmascience Inc (T-220-19) (FAMPYRA®)
  • T-1056-18 and T-998-16 (A-282-18 and A-283-18): Apotex Inc. v Shire LLC et al (T-1056-16) and Shire Pharma Canada ULC v Apotex Inc. (T-998-16) (VYVANSE®)
  • T-929-18: Galderma Canada Inc. et al v Apotex Inc. (APPRILON®)
  • T-40-18 (A-19-22/A-84-22): PSET LLC v Google Canada et al
  • T-1662-17: Crocs Canada Inc. et al v Double Diamond Distribution, Ltd.
  • T-1471-17: Pfizer Canada Inc. v Genentech, Inc. (AVASTIN®)
  • T-1260-16 and T-1262-16: Novartis Pharmaceuticals Canada Inc. v Teva Canada Limited et al (AFINITOR®)
  • T-448-16: Galderma Canada Inc. v Taro Pharmaceuticals Inc. et al (TACTUPUMP®)
  • T-123-15; T-311-12; T-546-12: Bauer Hockey Ltd. v Sport maska Inc. dba CCM Hockey
  • T-1392-14: Shire Canada Inc. v Apotex Inc. et al (ADDERALL XR®)
  • T-852-14 (A-96-16): Allergan Inc v Apotex Inc. et al (ZYMAR®)
  • T-365-14: Novartis Pharmaceuticals Canada Inc. v Mylan Pharmaceuticals ULC et al (EXELON®)
  • T-259-14: Shire Canada Inc. v Pharmascience Inc. et al (ADDERALL XR®)
  • T-1472-13: Shire Canada Inc. v Cobalt Pharmaceuticals Company et al (ADDERALL XR®)
  • CV-13-00492419: Apotex Inc. v Eli Lilly Canada et al (ZYPREXA®)
  • T-1095-13 (A-404-15): Novartis Pharmaceuticals Canada Inc. v Teva Canada Limited et al (EXJADE®)
  • T-450-13 and T-451-13: Shire Canada Inc. v Mylan Pharmaceuticals ULC et al (FOSRENOL®)
  • A-98-13 and A-99-13 (T-2021-10 and others): Apotex Inc. v Novartis AG; Teva Canada Limited v Novartis Pharmaceuticals Inc. et al (GLEEVEC®)
  • T-238-13: Novartis Pharmaceuticals Canada Inc. v Cobalt Pharmaceuticals Co et al (EXELON®)
  • T-2289-12: Novartis Pharmaceuticals Canada Inc. v Cobalt Pharmaceuticals Co et al (GLEEVEC®)
  • T-1156-12 (A-483-15): Gilead Sciences, Inc. et al v Idenix Pharmaceuticals Inc., et al (SOVALDI®)
  • T-1247-11: Hoffman-La Roche Limited v. Apotex Inc. et al (VALCYTE®)